Childhood cancers: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• NF1 12
• ABL1 2
• HER2 25
• PI3K 5
• AKT 1
• CDK4/6 7
• PD-L1 13
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• KMT2A 12
• PSMA 20
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• RAS 1
• CD38 5
• EZH2 0
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

5 of 5+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

  NCT04952584· Baylor College of Medicine· Updated 7 Sept 2023

  “Study was not activated”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

  NCT04213209· Takeda· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 522
• Machine Learning 69
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study.

  Eur J Cancer, Oct 2026

• Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing.

  Med Sci (Basel), Sept 2026

  Aditya Kumar Gupta

• T-rex: standardized analysis of germline variants in whole-exome sequencing trios.

  Sci Rep, Aug 2026

• Clinical characteristics and variant spectrum of NF1 in Chinese patients with neurofibromatosis type 1: a cross-sectional study.

  Orphanet J Rare Dis, Aug 2026

• Effect of ARHGAP9 on Chemoresistance in High-Risk Advanced Retinoblastoma via the Rac1/β-Catenin/LEF1 Signaling Axis.

  Invest Ophthalmol Vis Sci, Aug 2026

• Novel Germline ELP1 Splice-Acceptor Variant in NF1-Negative Optic Pathway Glioma: Expanding the Clinical Spectrum Associated With ELP1 Variation.

  Clin Genet, Jul 2026

• Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

  Clin Pharmacol Ther, Jun 2026

• Genotypic and phenotypic features of 23 Egyptian patients with tuberous sclerosis complex.

  BMC Pediatr, Jun 2026

• Prenatal diagnosis of cardiac rhabdomyoma: implications for predicting tuberous sclerosis complex and guiding perinatal management.

  Ultrasound Obstet Gynecol, Jun 2026

• Expanding the spectrum of H3K27-altered gliomas: Hemispheric cases with midline epigenetic signatures.

  Ann Diagn Pathol, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.